Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Advertisement
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

Germany Heads List Of EU Countries Taking On UK’s RMS Roles

Companies still need to replace the UK as their reference member state for around 6,000 products in Europe’s decentralized and mutual recognition procedures. Of the switches that have been completed so far, many have gone to Germany.

Europe United Kingdom

Keep Us In The Loop: EMA Clarifies Expectations Following PRIME Kick-Off Meetings

New guidance from the European Medicines Agency explains how sponsors that have drugs in its priority medicines scheme should interact with its experts and committees.

Market Access Europe

Why Four In Five Applications For PRIME Still Fail Two Years On: EMA Clarifies Expectations

The European Medicines Agency’s priority medicines scheme, PRIME, attracts a lot of applications, but most of them fail. The agency has explained why and has updated it guidance documents for applicants.

Market Access Europe

EMA’s PRIME Is Driving Innovation, But Too Early To Tell If Drugs Will Reach Patients Faster

With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.

Market Access Research & Development

Can’t Meet The Brexit Deadline? EU Regulators To Find ‘Flexible Solutions’ For Industry

With less than 11 months left to prepare for Brexit, companies with drugs in Europe’s decentralized and mutual recognition procedures are being urged to tell regulators if they are struggling to make the necessary changes by the March 2019 deadline for the UK to leave the EU.

Brexit Europe

Definitive Data Hopes Keep Santhera's Duchenne Drug Alive in UK Despite EMA No

The European Medicines Agency rejected Santhera’s Raxone as a treatment for Duchenne muscular dystrophy but the prospect of definitive data supporting the new indication means idebenone will still be available to patients in the UK under the early access scheme for promising new medicines. 

Market Access United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register